Since the opening up of trade ASEAN countries, China exports to the ASEAN pharmaceutical products showed a rapid growth trend, the export volume and export value of the average annual growth rate reached double digits. Since 2002, China and ASEAN trade between the medicine nearly 40% average annual growth rate of rise, showing a steady increase in the total, the price continued to rise, the total rose steadily, the market is relatively concentrated momentum. China has become Indonesia, Vietnam, the Philippines and other ASEAN countries, the largest pharmaceutical importer.
Export products in the medical, pharmaceutical raw materials the largest proportion, 75% or so. December 2009, the Chinese medicine products exported to ASEAN reached $ 176 million, an increase of 65.3%, than the Chinese medicine products on the global export growth higher than 30 percentage points. Among them, pharmaceutical raw materials exports $ 132 million, an increase of 50.5%, accounting for about 75% of Western exports. API of antipyretic analgesics, hormones, tetracyclines, and other anti-infective pharmaceutical raw material exports have more substantial increase. Anti-inflammatory drugs in China's major export region, the ASEAN region alone accounts for nearly one-quarter, well above 17% in Europe and North America 15% of GDP.
In particular, in 2010, China - ASEAN Free Trade Area officially completed, benefiting from the completion of the FTA and tariff reduction brought about by the of the Chinese pharmaceutical raw materials exports to ASEAN grew very rapidly, including Indonesia, Thailand and Vietnam, particularly growth significant. In 2010 China's exports to ASEAN amounted to Western products $ 2.094 billion, accounting for 58.54% of total health care category, exports of raw materials in medicine, antipyretic analgesics, anti-infective, resveratrol, vitamins, hormones, glutamine acid, citric acid as the main species. The next few years the prospects of ASEAN exports to China pharmaceutical raw materials will remain very substantial.
There are currently 10 member countries of ASEAN, the land area of
​​about 4.46 million square kilometers, a population of nearly 600 million, accounting for 8.5% of the total world population is about. By population growth, political stability, rapid economic development, the traditional way of life change and the increasing health awareness and other factors driving the ASEAN pharmaceutical market in recent years show rapid growth, import demand for pharmaceutical products has also become enlarged. Especially in recent years, many ASEAN countries, more and more attention for the cause of public health, increasing government investment, and promote the pharmaceutical market continues to heat up.
Thailand as ASEAN's largest pharmaceutical market, per capita drug expenditures of approximately $ 55, the Chinese medicine products is the fastest export growth of ASEAN countries. Thailand started in 2001, medical insurance plan. Beginning in 2010, Thailand implemented for children under 6 free medical care, thus a significant increase in the number of children for medical treatment, giving rise to medical demand. Recently, the Ministry of Health has submitted to the Cabinet to expand health care coverage on a new plan. The program aims to increase per capita health care subsidies, expected from 2011 onwards, the future of Thailand's per capita health care subsidies will be increased to $ 67.8, 2013, Thailand's health care spending will increase to $ 16.1 billion, accounting for 4.1% of GDP.
Indonesia as the ASEAN's second largest pharmaceutical market, is the most import of Chinese medicine products of ASEAN countries. Indonesia needs a variety of pharmaceutical raw materials, 90% dependent on imports, the major importing countries of China and India. Meanwhile, Indonesia's per capita drug expenditures of approximately $ 12.5 to generic drugs and OTC drugs based. As the Indonesia patent medicine on the market less, plant extracts while the share of generic drugs continues to expand, accounting for 70% of the total pharmaceutical market to 80%. To encourage the use of generic drugs, the Government of Indonesia to provide subsidies for local producers to encourage production of pharmaceutical raw materials required for the import of essential drugs, which makes pharmaceutical raw materials in China's exports to Indonesia will maintain a high long-term growth.
Can be said that the ASEAN pharmaceutical market pharmaceutical raw materials 90% dependent on imports, the demand for quality and cheap generic drugs is also increasing, especially since China and ASEAN signed a Free Trade Agreement, its dependence on the pharmaceutical raw materials in China higher and higher. Especially anti-inflammatory drugs, anti-infective, vitamins, digestive and respiratory drugs such as efficacy, clinical need, low cost, mass of the basic generic drugs, the rigidity of the market demand is very strong, pharmaceutical raw materials for future ASEAN market China's demand for drugs will continue to rise. Source:http://www.cospcn.com